[1] 陈红松, 窦晓光, 段钟平,等. 丙型肝炎防治指南(2015年更新版). 临床肝胆病杂志, 2015, 31: 1961-1979.
[2] 彭焕彦, 杨二娜, 孙殿兴. 索非布韦治疗慢性丙型肝炎的研究进展. 临床肝胆病杂志, 2016, 32: 798-801.
[3] Iqbal S, Yousuf MH, Yousaf MI. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study. World J Gastroenterol, 2017, 23: 7899-7905.
[4] Sperl J, Frankova S, Kreidlova M, et al. Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis. Ther Clin Risk Manag, 2017, 13: 733-738.
[5] Kanwal F, Kramer JR, Ilyas J, et al. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology, 2014, 60: 98-105.
[6] Tapper EB, Afdhal NH. Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3. J Viral Hepat, 2013, 20: 669-677. |
